The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J. M., Wang, Z., Philip, P. A., & Sarkar, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4598 · Cited by 424
RetractedDuxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207272 · Cited by 224
RetractedCancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Castillo, C. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,480
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., & Raber, M. N. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.491 · Cited by 759
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Li, Y., VandenBoom, T. G., Kong, D., Wang, Z., Ali, S., Philip, P. A., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1298 · Cited by 663
Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S., Abbruzzese, J. L., Gallick, G. E., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4312 · Cited by 619
Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis
Vlodavsky, I., & Friedmann, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13662 · Cited by 618
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., YOUNG, J., Belt, J. A., Crawford, C. R., & Cass, C. E. (1998) · PubMed · Cited by 599
Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J., & Aggarwal, B. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4257 · Cited by 578
Heinemann, V., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1988) · PubMed · Cited by 504
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Arlt, A., Gehrz, A., Müerköster, S., Vorndamm, J., Kruse, M.-L., Fölsch, U. R., & Schäfer, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206390 · Cited by 474
Giovannetti, E., Funel, N., Peters, G. J., Del Chiaro, M., Erozenci, L. A., Vasile, E., Leon, L. G., Pollina, L. E., Groen, A., Falcone, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4467 · Cited by 457
Kanai, M., Yoshimura, K., Asada, M., Imaizumi, A., Suzuki, C., Matsumoto, S., Nishimura, T., Mori, Y., Masui, T., Kawaguchi, Y., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1470-2 · Cited by 399
Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4203 · Cited by 351
Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333
Nakano, Y., Tanno, S., Koizumi, K., Nishikawa, T., Nakamura, K., Minoguchi, M., Izawa, T., Mizukami, Y., Okumura, T., & Kohgo, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603559 · Cited by 328
Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1992) · PubMed · Cited by 328
Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 323
Stromal biology of pancreatic cancer
Chu, G. C., Kimmelman, A. C., Hezel, A. F., & DePinho, R. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21209 · Cited by 317
(2000) · PubMed · Cited by 310
Park, J.-K., Lee, E. J., Esau, C., & Schmittgen, T. D. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181ba82e1 · Cited by 287
Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J., & Gil, Z. (2014) · Oncogene · doi:10.1038/onc.2013.357 · Cited by 281
Self-citationIjichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42754 · Cited by 256
Calabretta, S., Bielli, P., Passacantilli, I., Pilozzi, E., Fendrich, V, Capurso, G., Fave, G. D., & Sette, C. (2016) · Oncogene · doi:10.1038/onc.2015.270 · Cited by 249
Garrido-Laguna, I., Uson, M., Rajeshkumar, N. V., Tan, A. C., de Oliveira, E., Karikari, C., Villaroel, M. C., Salomon, A., Taylor, G., Sharma, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0341 · Cited by 247
Goan, Y.-G., Zhou, B., Hu, E., Mi, S., & Yen, Y. (1999) · PubMed · Cited by 227
Singh, S., Srivastava, S. K., Bhardwaj, A., Owen, L. B., & Singh, A. P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605968 · Cited by 225
Maréchal, R., Mackey, J. R., Lai, R., Demetter, P., Peeters, M., Polus, M., Cass, C. E., Young, J., Salmon, I., Devière, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2080 · Cited by 219
Nakahira, S., Nakamori, S., Tsujie, M., Takahashi, Y., Okami, J., Yoshioka, S., Yamasaki, M., Marubashi, S., Takemasa, I., Miyamoto, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22390 · Cited by 209
Jones, L. E., Humphreys, M. J., Campbell, F., Neoptolemos, J. P., & Boyd, M. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1157-03 · Cited by 200
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1183-3 · Cited by 192
Moorsel, C. J. A. V., Pinedo, H. M., Veerman, G., Bergman, A. M., Kuiper, C. M., Vermorken, J. B., van der Vijgh, W. J. F., & Peters, G. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690452 · Cited by 192
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep, J. R., Loves, W. J. P., van der Wilt, C. L., Álvarez, E., Talianidis, I., Boven, E., Braakhuis, B. J. M., van Groeningen, C. J., Pinedo, H. M., & Peters, G. J. (2002) · PubMed · Cited by 191
Määttä, M., Soini, Y., Liakka, A., & Autio‐Harmainen, H. (2000) · PubMed · Cited by 178
Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
Kim, M. P., & Gallick, G. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2247 · Cited by 177
Dangi-Garimella, S., Krantz, S. B., Barron, M. R., Shields, M. A., Heiferman, M. J., Grippo, P. J., Bentrem, D. J., & Munshi, H. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1855 · Cited by 176
van Haperen, V. W. T. R., Veerman, G., Eriksson, S., et al. (1994) · PubMed · Cited by 168
Akada, M., Crnogorac-Jurcevic, T., Lattimore, S., Mahon, P., Lopes, R., Sunamura, M., Matsuno, S., & Lemoine, N. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1785 · Cited by 168
An Undesired Effect of Chemotherapy
Arora, S., Bhardwaj, A., Singh, S., Srivastava, S. K., McClellan, S., Nirodi, C. S., Piazza, G. A., Grizzle, W. E., Owen, L. B., & Singh, A. P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.484576 · Cited by 166
Servais, C., & Erez, N. (2012) · The Journal of Pathology · doi:10.1002/path.4103 · Cited by 161
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine
Donadelli, M., Costanzo, C., Beghelli, S., Scupoli, M. T., Dandrea, M., Bonora, A., Piacentini, P., Budillon, A., Caraglia, M., Scarpa, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.002 · Cited by 157
Dumontet, C., Fabianowska‐Majewska, K., Mantincic, D., Callet‐Bauchu, E., Tigaud, I., Gandhi, V. V., Lepoivre, M., Peters, G. J., Rolland, M. O., Wyczechowska, D. D., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01509.x · Cited by 151
Bergman, A. M., Pinedo, H. M., Talianidis, I., Veerman, G., Loves, W. J. P., van der Wilt, C. L., & Peters, G. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601011 · Cited by 151
Achiwa, H., Oguri, T., Sato, S., 前田, 浩., Niimi, T., & Ueda, R. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03257.x · Cited by 147
Hruban, R. H., & Fukushima, N. (2007) · Modern Pathology · doi:10.1038/modpathol.3800685 · Cited by 142
Guillermet‐Guibert, J., Davenne, L., Pchejetski, D., Saint‐Laurent, N., Brizuela, L., Guilbeau‐Frugier, C., Delisle, M., Cuvillier, O., Susini, C., & Bousquet, C. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1096 · Cited by 141
Guo, X., Xu, B., Pandey, S., Goessl, E., Brown, J. E. P., Armesilla, A. L., Darling, J. L., & Wang, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.002 · Cited by 138
Ju, H.-Q., Gocho, T., Aguilar, M., Wu, M., Zhuang, Z.-N., Fu, J., Yanaga, K., Huang, P., & Chiao, P. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0420 · Cited by 137
Hamada, S., Masamune, A., Miura, S., Satoh, K., & Shimosegawa, T. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.11.003 · Cited by 136
Poon, C. J., He, C., Liu, D., Lu, K., & Lin, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.026 · Cited by 136
Singh, R., & Saini, N. (2012) · Journal of Cell Science · doi:10.1242/jcs.095976 · Cited by 135
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
Akita, H., Zheng, Z., Takeda, Y., Kim, C. Y., Kittaka, N., Kobayashi, S., Marubashi, S., Takemasa, I., Nagano, H., Dono, K., et al. (2009) · Oncogene · doi:10.1038/onc.2009.158 · Cited by 129
Pan, X., Arumugam, T., Yamamoto, T., Levin, P. A., Ramachandran, V., Ji, B., Lopez‐Berestein, G., Vivas‐Mejía, P. E., Sood, A. K., McConkey, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1539 · Cited by 129
Friend or foe: the role of microRNA in chemotherapy resistance
Li, H., & Yang, B. B. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.35 · Cited by 118
Li, H., & Yang, B. B. (2012) · Oncotarget · doi:10.18632/oncotarget.810 · Cited by 117
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., Mano, N., Nakano, T., Lee, Y., Shimizu, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.122 · Cited by 114
Kelber, J. A., Reno, T. A., Kaushal, S., Metildi, C. A., Wright, T., Stoletov, K. V., Weems, J. M., Park, F. D., Mose, E. S., Wang, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3552 · Cited by 114
Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers.
Yang, Y., Liu, H., Li, Z., Zhao, Z., Yip-Schneider, M., Fan, Q., Schmidt, C. M., Chiorean, E. G., Xie, J., Liang Cheng, C., et al. (2011) · PubMed Central · Cited by 109
Proteasome Inhibition Sensitizes Non–Small-Cell Lung Cancer to Gemcitabine-Induced Apoptosis
Denlinger, C. E., Rundall, B. K., Keller, M. D., et al. (2004) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2004.04.029 · Cited by 109
Jung, C. P., Motwani, M., & Schwartz, G. K. (2001) · PubMed · Cited by 106
Arnold, N. B., Arkus, N. L. A., Gunn, J. R., & Korc, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0914 · Cited by 104
Zhao, Y., Zhao, L., Ischenko, I., Bao, Q., Schwarz, B., Nieß, H., Wang, Y., Renner, A., Mysliwietz, J., Jauch, K., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0360-2 · Cited by 101
Expression of a non‐functional p53 affects the sensitivity of cancer cells to gemcitabine
Galmarini, C. M., Clarke, M. L., Falette, N., Puisieux, A., Mackey, J. R., & Dumontet, C. (2001) · International Journal of Cancer · doi:10.1002/ijc.1628 · Cited by 100
Fukunaga, A. K., Marsh, S., Murry, D. J., Hurley, T. D., & McLeod, H. L. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500259 · Cited by 99
Tjomsland, V., Niklasson, L., Sandström, P., Borch, K., Druid, H., Bratthäll, C., Messmer, D., Larsson, M., & Spångéus, A. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/212810 · Cited by 99
Sliutz, G., Karlseder, J., Tempfer, C. M., Orel, L., Holzer, G., & Simon, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.334 · Cited by 98
Kroep, J. R., Giaccone, G., Tolis, C., Voorn, D. A., Loves, W. J. P., van Groeningen, C. J., Pinedo, H. M., & Peters, G. J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1399 · Cited by 93
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Pourquier, P., Gioffre, C., Kohlhagen, G., Urasaki, Y., Goldwasser, F., Hertel, L. W., Yu, S., Pon, R. T., Gmeiner, W. H., & Pommier, Y. G. (2002) · PubMed · Cited by 93
Giroux, V., Iovanna, J., & Dagorn, J. (2006) · The FASEB Journal · doi:10.1096/fj.06-6239com · Cited by 90
Habiro, A., Tanno, S., Koizumi, K., Izawa, T., Nakano, Y., Osanai, M., Mizukami, Y., Okumura, T., & Kohgo, Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.017 · Cited by 85
Ge, Y., Jensen, T. L., Stout, M. L., Flatley, R. M., Grohar, P. J., Ravindranath, Y., Matherly, L. H., & Taub, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2456 · Cited by 84
Yoon, H., Min, J., Lee, J. W., Kim, D., & Hong, H. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.130 · Cited by 81
Integrating pharmacogenetics into gemcitabine dosing—time for a change?
Ciccolini, J., Mercier, C., Dahan, L., & André, N. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.1 · Cited by 79
Liang, C., Yu, X., Guo, X., Sun, M.-H., Wang, Z., Song, Y. H., Ni, Q.-X., Li, H., Mukaida, N., & Li, Y.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3885 · Cited by 78
Chun, S. G., Zhou, W., & Yee, N. S. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.14.8633 · Cited by 76
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Gandhi, V. V., Legha, J., Chen, F., Hertel, L. W., & Plunkett, W. K. (1996) · PubMed · Cited by 76
Namba, T., Kodama, R., Moritomo, S., Hoshino, T., & Mizushima, T. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.172 · Cited by 75
van Haperen, V. W. T. R., Veerman, G., Vermorken, J. B., Pinedo, H. M., & Peters, G. J. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02402-6 · Cited by 75
Jordheim, L. P., Guittet, O., Lepoivre, M., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0121 · Cited by 66
Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line
Jordheim, L. P., Cros‐Perrial, E., Gouy, M.-H., Galmarini, C. M., Peyrottes, S., Mackey, J. R., Périgaud, C., & Dumontet, C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0506 · Cited by 65
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts
van Haperen, V. W. T. R., Veerman, G., Braakhuis, B. J. M., Vermorken, J. B., Boven, E., LEYVA, A., & Peters, G. J. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90048-k · Cited by 58
Advances in targeted therapy for unresectable melanoma: New drugs and combinations
Hao, M., Song, F., Du, X., Wang, G., Yang, Y. P., Chen, K., & Yang, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.050 · Cited by 57
Maehara, S., Tanaka, S., Shimada, M., Shirabe, K., Saito, Y., Takahashi, K., & Maehara, Y. (2004) · International Journal of Cancer · doi:10.1002/ijc.20304 · Cited by 55
Jimeno, A., Rubio‐Viqueira, B., Rajeshkumar, N. V., Chan, A., Solomon, A., & Hidalgo, M. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0693 · Cited by 53
Purushothaman, A., Babitz, S. K., & Sanderson, R. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.391417 · Cited by 51
Liang, K., Lü, Y., Li, X., Zeng, X., Glazer, R. I., Mills, G. B., & Fan, Z. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023333 · Cited by 50
Lin, X., & Howell, S. B. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.2.390 · Cited by 45
A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines
Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Taba, K., Fujimoto, M., Okita, K., Nakamura, K., & Sakaida, I. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.3.429 · Cited by 44
MicroRNA-gene signaling pathways in pancreatic cancer
Iliopoulos, D., & Drakaki, A. (2013) · Biomedical Journal · doi:10.4103/2319-4170.119690 · Cited by 44
Kuramitsu, Y., Taba, K., Ryozawa, S., et al. (2010) · PubMed · Cited by 43
Hung, S. W., Marrache, S., Cummins, S., Bhutia, Y. D., Mody, H. R., Hooks, S. B., Dhar, S., & Govindarajan, R. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.017 · Cited by 39
Bahra, M., Kamphues, C., Boas‐Knoop, S., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e31822896dd · Cited by 32
Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells
Bergman, A. M., Pinedo, H. M., & Peters, G. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00858-5 · Cited by 24
Tokunaga, Y., Liu, D., Nakano, J., Zhang, X., Nii, K., Go, T., Huang, C., & Yokomise, H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.013 · Cited by 22
Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms
Lecca, P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.026 · Cited by 14
Cited by
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Binenbaum, Y., Fridman, E., Yaari, Z., Milman, N., Schroeder, A., Ben David, G., Shlomi, T., & Gil, Z. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0124 · Cited by 337
Self-citationQi, R., Bai, Y., Li, K., Liu, N., Xu, Y., Dal, E., Wang, Y., Lin, R., Wang, H., Liu, Z., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100960 · Cited by 307
Metadata
- Authors
- Binenbaum, Y., Na’ara, S., & Gil, Z.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 23
- Pages
- 55-68
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2192943385
- Cited by
- 414
- References
- 110
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.